Table 2.
Association of HLA-B alleles with carbamazepine-induced cADRs.
| HLA-B alleles | Carbamazepine-induced cADRs (n = 38) | Controls (n = 271) | Thai population (n = 470) | Carbamazepine-induced cADRs cases versus tolerant controls | Carbamazepine-induced cADRs cases versus Thai population | ||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||||
| B∗07:05 | 3 (7.89%) | 12 (4.43%) | 24 (5.11%) | 1.85 (0.50–6.88) | 0.357 | 1.59 (0.46–5.55) | 0.4649 |
| B∗13:01 | 1 (2.63%) | 37 (13.65%) | 54 (11.49%) | 0.17 (0.02–1.28) | 0.063 | 0.21 (0.03–1.55) | 0.106 |
| B∗13:02 | 1 (2.63%) | 6 (2.21%) | 20 (4.26%) | 1.19 (0.14–10.19) | 1.000 | 0.61 (0.08–4.66) | 1.000 |
| B∗15:01 | 1 (2.63%) | 10 (3.69%) | 5 (1.06%) | 0.71 (0.09–5.67) | 1.000 | 2.51 (0.29–22.08) | 0.374 |
| B∗15:02 | 17 (44.74%) | 11 (4.06%) | 71 (15.11%) | 19.13 (7.94–46.09) | 7.35 × 10−12∗ | 4.55 (2.29–9.05) | 3.44 × 10−6∗ |
| B∗15:21 | 2 (5.26%) | 4 (1.48%) | 2 (0.43%) | 3.71 (0.66–20.97) | 0.161 | 13.00 (1.78–95.01) | 0.030∗ |
| B∗18:01 | 4 (10.53%) | 29 (10.70%) | 36 (7.66%) | 0.98 (0.33–2.97) | 0.974 | 1.42 (0.48–3.22) | 0.529 |
| B∗18:15 | 2 (5.26%) | 0 (0.00%) | 0 (0.00%) | 15.06 (1.33–170.25) | 0.041∗ | 26.11 (2.31–294.90) | 0.016∗ |
| B∗27:04 | 2 (5.26%) | 12 (4.43%) | 19 (4.04%) | 1.20 (0.26–5.58) | 0.685 | 1.32 (0.30–5.89) | 0.665 |
| B∗27:06 | 1 (2.63%) | 8 (2.95%) | 12 (2.55%) | 0.89 (0.11–7.31) | 1.000 | 1.03 (0.13–8.15) | 1.000 |
| B∗40:01 | 5 (13.16%) | 41 (15.13%) | 58 (12.34%) | 0.85 (0.31–2.31) | 0.749 | 1.08 (0.40–2.87) | 0.883 |
| B∗44:03 | 3 (7.89%) | 20 (7.38%) | 42 (8.94%) | 1.08 (0.30–3.81) | 0.910 | 0.47 (0.14–1.59) | 0.223 |
| B∗46:01 | 8 (21.05%) | 64 (23.62%) | 122 (25.96%) | 0.86 (0.38–1.98) | 0.718 | 0.77 (0.34–1.72) | 0.524 |
| B∗51:01 | 5 (13.16%) | 21 (7.75%) | 40 (8.51%) | 1.80 (0.64–5.11) | 0.267 | 1.63 (0.60–4.41) | 0.337 |
| B∗56:04 | 1 (2.63%) | 1 (0.37%) | 12 (2.55%) | 7.30 (0.45–119.17) | 0.231 | 1.03 (0.13–8.15) | 1.000 |
| B∗57:01 | 1 (2.63%) | 9 (3.32%) | 11 (2.34%) | 0.79 (0.10–6.39) | 1.000 | 1.13 (0.14–8.98) | 0.611 |
| B∗58:01 | 8 (21.05%) | 22 (8.12%) | 57 (12.13%) | 3.02 (1.24–7.38) | 0.015∗ | 1.93 (0.85–4.42) | 0.119 |
cADRs: cutaneous adverse drug reactions; OR: odds ratio; 95% CI: confidence interval 95%. ∗P value less than 0.05.